Product launches are the moments when years of research, development, and investment translate into patient access and revenue. For pharmaceutical companies, the quality of launch execution often determines the long-term commercial trajectory of a product as much as the clinical profile itself. CEOs understand this intuitively, which is why launch readiness is also one of the areas where executives most commonly struggle to maintain the right delegation discipline.
The pull toward CEO micromanagement of launch preparation is understandable: the stakes are high, the activities are complex, and the visibility is intense. But launch readiness is fundamentally a cross-functional operational discipline that performs best when the relevant functional leaders own their domains with clear accountability, aligned timelines, and strong cross-functional coordination. The CEO’s most valuable contributions to launch readiness are ensuring organizational alignment, removing systemic barriers, and making the portfolio-level decisions that affect launch investment and prioritization.
The Scope of Pre-Launch Readiness
Pre-launch readiness encompasses a wide range of activities across multiple functions. A complete launch readiness program typically includes:
Commercial readiness: field force hiring, training, and deployment; market access and reimbursement strategy; pricing strategy; marketing material development and approval; speaker bureau development; and launch event planning.
Medical affairs readiness: medical information capabilities; publication strategy execution; health economics and outcomes research; KOL engagement; medical education programs; and MSL (Medical Science Liaison) deployment.
Regulatory affairs readiness: managing the final stages of the regulatory submission, responding to agency questions, preparing for advisory committee hearings, and developing the prescribing information strategy.
Supply chain readiness: ensuring adequate product supply for launch, managing distribution partnerships, preparing for demand variability, and implementing serialization and traceability requirements.
Market access readiness: developing payer value dossiers, executing payer contracting strategy, managing formulary negotiations, and preparing patient access programs.
IT and operations readiness: ensuring systems are ready to support launch activities including order management, adverse event reporting, call center operations, and data analytics.
The Delegation Architecture for Launch Readiness
Effective delegation of launch readiness requires a clear organizational structure that assigns functional accountability while enabling the cross-functional coordination that launch success demands.
Launch steering committee and launch leader
Most pharma companies appoint a dedicated launch director or VP of Launch who is accountable for overall launch readiness coordination. This individual does not own all of the functional activities but is accountable for ensuring that all functions are on track against the launch readiness plan, that cross-functional dependencies are managed, and that issues are escalated appropriately.
The CEO should hold the launch director accountable for launch readiness as a whole, while each functional leader is accountable to the launch director and to the CEO for their functional domain.
Functional launch readiness owners
Each major function should have a single accountable leader for their launch readiness domain:
The Chief Commercial Officer (CCO) owns commercial readiness, including field force, marketing, and market access. The Chief Medical Officer (CMO) owns medical affairs readiness. The Head of Regulatory owns regulatory readiness. The Head of Supply Chain owns supply readiness. The Head of IT owns systems readiness.
These functional owners should have the authority, resources, and accountability to drive their functional launch readiness without CEO involvement in specific activities.
Cross-functional launch team
Below the steering committee level, a cross-functional launch team meets weekly or bi-weekly to coordinate activities, resolve cross-functional dependencies, and identify emerging issues. This team is led by the launch director and includes working-level representatives from each function.
The CEO should not be a standing member of this team. The cross-functional launch team should operate as a self-managing coordination mechanism, with escalation paths to functional leaders and the launch steering committee for issues that cannot be resolved at the team level.
What the CEO Should Own in Launch Readiness
Even with robust delegation, the CEO should retain personal accountability for several key launch decisions and activities:
Portfolio launch prioritization: When a company has multiple launches in a defined period, the CEO must make or approve the prioritization decisions about where investment and organizational attention are concentrated. These decisions affect resource allocation, field force sizing, and the relative emphasis on different market segments.
Launch investment level: Major decisions about launch investment, including field force size, marketing budget, and market access resources, have material financial implications that require CEO and CFO approval.
Significant pricing and access decisions: Pricing and market access decisions for major products are high-stakes strategic choices that can affect not just the product’s commercial success but also the company’s relationships with payers and policy makers. The CEO should be directly involved in approving major pricing and access strategies.
Organizational readiness for cross-functional alignment: When cross-functional tensions or resource conflicts threaten launch readiness, the CEO may need to directly intervene to resolve competing priorities. Launch readiness often reveals organizational coordination failures that require CEO-level resolution.
External launch communications: Major public announcements around launch, including investor communications, media announcements, and key customer presentations, should involve the CEO as the primary or co-primary spokesperson.
Managing Launch Readiness Reviews
The primary mechanism through which the CEO maintains visibility into launch readiness is the launch readiness review. A well-structured launch readiness review gives the CEO a consolidated picture of readiness status across all functions without requiring engagement in the details of any individual function.
A typical launch readiness review structure includes:
Monthly executive launch readiness review (90 minutes): The launch director presents a functional readiness dashboard showing status (on-track, at-risk, behind) for each major launch readiness domain. Functional leaders present on any domains that are at risk and the plans to address gaps. The CEO reviews overall readiness status and makes any decisions required to resolve issues.
Quarterly deep-dive review: A more detailed review of launch strategy and readiness, covering competitive positioning, market access progress, field force deployment status, and supply chain readiness in greater depth.
Launch readiness gate reviews: At defined milestones (typically T minus 12 months, T minus 6 months, and T minus 3 months), a formal gate review assesses overall launch readiness against defined criteria. These reviews may involve the board or board sub-committee for major launches.
Common Delegation Failures in Launch Readiness
Several common delegation failures recur in pharmaceutical launch readiness:
CEO micromanagement of commercial details. When CEOs attend field force training sessions, review individual marketing materials, or participate in market research debriefs, they are investing time in work that should be fully delegated to the commercial team. This behavior also signals to the commercial team that the CEO does not trust their judgment, which undermines their confidence and initiative.
Insufficient authority for the launch director. When the launch director lacks organizational authority to hold functional leaders accountable, cross-functional coordination breaks down. The CEO should ensure that the launch director role has genuine authority to demand accountability and escalate issues.
Late integration of market access. Market access and reimbursement strategy often receives insufficient attention until relatively late in launch preparation. The CEO should ensure that market access is treated as a first-tier launch readiness domain alongside commercial and medical affairs, not a secondary consideration addressed after the clinical and marketing work is done.
Underinvestment in IT and systems readiness. Systems failures on launch day (order management, adverse event reporting, patient services platforms) can create operational crises that divert attention from the commercial launch. Systems readiness should be a standing item in launch readiness reviews.
For related guidance on launch team management, the supply chain delegation guide addresses supply readiness in detail. The regulatory affairs delegation guide covers regulatory launch readiness governance.
Building a Culture of Launch Excellence
Successful launches are not just the product of good planning and execution; they also reflect the organizational culture and values that the CEO models. Companies that consistently execute excellent launches share several cultural characteristics: a bias toward action, accountability at every level, cross-functional collaboration without territorial defensiveness, and willingness to escalate and resolve issues quickly rather than managing them to avoid conflict.
The CEO’s role in building this culture is to model these behaviors in launch reviews and decision-making, to celebrate and recognize excellent launch execution, and to ensure that the organization learns from both successful and challenging launches through post-launch reviews.
A formal post-launch review process (90 days after launch) that identifies what worked, what did not, and what should be done differently for the next launch is a valuable investment in organizational learning. This review should be led by the launch director with CEO participation in the summary session.
The Board’s Role in Major Launches
For major product launches representing significant value for the company, the board should be kept informed of launch readiness status and should approve major investment and resource decisions. The CEO is the primary liaison between management and the board on launch matters.
A brief launch readiness update at each board meeting in the 12 to 18 months before launch is a reasonable governance mechanism. The CEO and launch director should prepare this update together, with the CEO presenting the strategic context and the launch director presenting the operational readiness status.
Conclusion
Pre-launch readiness is an inherently cross-functional, high-stakes activity that demands both strong delegation and clear CEO leadership. The delegation framework described here gives pharma CEOs a practical structure for maintaining strategic oversight of launch preparation while allowing the commercial, medical, regulatory, and supply chain teams to own and execute their functional domains with full accountability. The best launch outcomes result from functional excellence combined with cross-functional alignment, with the CEO serving as the strategic integrator and issue resolver rather than the operational launch manager.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.